A growing literature points to an association between overactive bladder (OAB) medications and dementia. Given differences in side effects for extended‐release (ER) and immediate‐release (IR) anticholinergic formulations and beta‐3 agonists,… Click to show full abstract
A growing literature points to an association between overactive bladder (OAB) medications and dementia. Given differences in side effects for extended‐release (ER) and immediate‐release (IR) anticholinergic formulations and beta‐3 agonists, we examined prescription utilization patterns in a national dataset of older adults from 2014 to 2018.
               
Click one of the above tabs to view related content.